SWOG clinical trial number
S9804
Evaluation of Vinorelbine Tartrate (Navelbine®) in Patients with Disseminated Malignant Melanoma and at Least One Prior Systemic Therapy, Phase II.
Closed
Phase
Accrual
60%
Published
Research committees
Melanoma
Treatment
Vinorelbine tartrate
Eligibility Criteria Expand/Collapse
Pts. must have histologically confirmed, pathologically verified and surgically incurable malignant melanoma which is Stage IV; must have measurable disease; pts. with history of brain mets are eligible ONLY if they have been resected completely free of disease and then had whole brain RT; pts. must have had at least one prior systemic therapy (chemo, bio/immunotherapy, or a combination regimen) for metastatic disease which must have been completed at least 28 days prior to registration; pts. may have rec'd prior adjuvant bio or immunotherapy given in an adjuvant fashion which must have been completed at least 28 days prior to registation; pts. may not have rec'd prior adjuvant chemo; pts. may have rec'd prior RT; if all known sites of disease have been previously radiated, there must be objective evidence of progression for the pt. to be eligible; pt. may have rec'd prior surgery; PS 0-2; pts. with AIDS/HIV-1 associated complex or known to be HIV+ are not eligible.
Publication Information Expand/Collapse
2008
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]
2004
A phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study
2002
Evaluation of vinorelbine tartrate (navelbine) in patients with dissemminated malignant melanoma and at least one prior systemic therapy, phase II: a Southwest Oncology Group Study
2000
Evolution of combined modality therapy for stage III non-small-cell lung cancer
Other Clinical Trials
SWOG Clinical Trial Number
S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
91%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase